More on INSM
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $99.21 |
|
|||
| Open | $98.70 | ||||
| 52 Wk High | $19.30 | ||||
| 52 Wk Low | $9.02 | ||||
| Day High | $99.00 | ||||
| Day Low | $96.05 | ||||
| P/E | N/A | ||||
| EPS | $-1.69 | ||||
| Volume | 2,396,656 | ||||
- Insmed presents four-study TPIP lung disease trial program at CHEST 2026
- Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026
- Insmed to share respiratory data at CHEST 2026 and IDWeek 2026
- Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
- Truist Securitas's Biotechnology Earnings Preview: 'INSM, BBIO, NBIX Most Levered to the Print'
- Insmed (INSM) PT Lowered to $207 at BofA Securities
- Wolfe Research Downgrades Insmed (INSM) to Peerperform
- UBS Reiterates Buy Rating on Insmed (INSM) Into Q3 Earnings
- BMO Capital on Insmed (INSM): 'CFO Transition Less of a Concern w/ FY2026 Guidance Reaffirmed'
- RBC Capital maintains Outperform rating on Insmed amid CFO change
Entities mentioned with INSM
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- Definitive Agreement | View Related Stories »
- Stifel | View Related Stories »
- Show More...
